Recent Updates
Recently added Catalysts
BLCO Positive Sentiment Score: 75/100

Bausch + Lomb Delivers Broad-Based Second-Quarter Growth, Raises Full-Year 2026 Guidance

Wednesday, July 29, 2026 1 min read
Key Takeaway: Bausch + Lomb Corporation reported strong financial results for the second quarter of 2026, highlighting broad-based revenue growth and margin expansion. The company emphasized its ongoing progress in executing its three-year growth plan, which was initially presented at the Investor Day last November. The positive performance indicates effective management and operational improvements.

Market Sentiment Analysis

POSITIVE FACTORS

  • Broad-based revenue growth reported.
  • Margin expansion noted in financial results.
  • Continued progress on three-year growth plan.

Full Press Release Details

VAUGHAN, Ontario--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced its second-quarter 2026 financial results. “Broad-based revenue growth, leverage in the P&L, margin expansion and conversion to cash flow. These have been themes since we unveiled our three-year plan for growth at Investor Day last November, and in the second quarter progress continued at an accelerated pace

Frequently Asked Questions

What financial results did Bausch + Lomb report?

Bausch + Lomb reported broad-based revenue growth and margin expansion for Q2 2026.

What is the significance of the three-year growth plan?

The three-year growth plan aims to enhance revenue and operational efficiency, as highlighted during the Investor Day.

When was the Investor Day for Bausch + Lomb?

The Investor Day was held last November, where the growth plan was unveiled.

What does margin expansion indicate?

Margin expansion indicates improved profitability and operational efficiency within the company.

Tags: BLCO Viatris Investor Conferences Healthcare Bausch + Lomb financial results 2026 guidance revenue growth
Last updated: Jul 29, 2026

Biotech snapshot

Cash runway
$279M liquidity · $0M/mo burn
Low dilution risk
Lead asset
Latanoprostene bunodPhase 1
Intraocular Pressure →

Catalyst track record

+13%
best trade around BLCO's most recent catalyst

Peak hindsight return over a 120-day window, across 3 tracked FDA/PDUFA catalysts for BLCO.

See every catalyst's timing & PoA →